Company
Cardiol Therapeutics
TSE:CRDL
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (inflammation of the pericardium), which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the “ARCHER” trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
72 stories · page 2 of 4
Cardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditis
The study demonstrated that pharmaceutically manufactured cannabidiol – the active pharmaceutical ingredient in CardiolRx – significantly reduced pericardial effusion and thickening in a pre-clinical model of acute pericarditis
Cardiol Therapeutics to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heart
The company also said it will discontinue its LANCER trial, which was designed to investigate the cardioprotective properties of CardiolRx in patients hospitalized with COVID-19 due to a continuous decline in the number of eligible patients
Cardiol Therapeutics unveils new preclinical study results providing evidence of cardioprotective properties of CardiolRx
Results from the latest study help strengthen evidence of the cardioprotective properties of CardiolRx, suggesting anti-fibrotic mechanisms with therapeutic potential in heart failure
Cardiol Therapeutics says first patient enrolled in acute myocarditis trial of its oral cannabinoid formulation CardiolRx
CardiolRx is a pharmaceutically produced formulation being developed for the treatment of acute and chronic inflammation associated with heart disease
Cardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directors
"Their extensive and diversified experience will be invaluable to our continued growth and success as we advance the development of important new anti-fibrotic and anti-inflammatory therapeutics for the treatment of heart disease," said Dr
Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditis
Phase II is expected to enroll 25 patients at major clinical centers specializing in pericarditis in the US
Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascular disease
In a look back at its 2021 year, CEO David Elsley said the firm accomplished “several important goals” related to the development of its pharmaceutically produced cannabidiol formulations for use as an anti-fibrotic and anti-inflammatory th
Cardiol Therapeutics says Jennifer M. Chao has been appointed as director of the company
Chao has also been appointed chair of its Corporate Governance and Compensation Committee, the company said
Cardiol Therapeutics receives clearance to expand eligible patient group for its LANCER study
Eligible patients will now include vaccinated people, those treated with approved COVID-19 therapies under an emergency use authorization label, and patients with a prior history of smoking or obesity
Cardiol Therapeutics appoints three new members to its Scientific Advisory Board
The clinical-stage life sciences company welcomed Dr Paul Ridker, Dr Bruce McManus and Dr Joseph A Hill to the board